Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

April 30, 2015

Conditions
Urea Cycle DisordersCrigler Najjar Syndrome
Interventions
BIOLOGICAL

HepaStem

Trial Locations (11)

2650

Universitair Ziekenhuis (UZ) Antwerpen, Edegem

31059

Hôpital des Enfants, CHU de Toulouse, Toulouse

31096

Rambam Medical Center, Meyer Children's Hospital, Haifa

49202

Schneider Children's Medical Center of israel, Petah Tikva

59037

Hôpital Jeanne de Flandre, CHRU Lille, Lille

91240

Hadassah Ein-Kerem Medical Center, Jerusalem

94275

CHU Bicêtre, Le Kremlin-Bicêtre

Unknown

Saint Luc University Hospital, Brussels

00165

Ospedale Pediatrico Bambino Gesu di Roma, Roma

B4 6NH

Birmingham Children's Hospital, Birmingham

WC1N 3JH

Great Ormond Street Hospital London, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cellaion SA

INDUSTRY